CoChat

Methylphenidate use in males with Duchenne muscular dystrophy and a comorbid attention-deficit hyperactivity disorder

Lionarons, Judith M., Hellebrekers, Danique M.J., Klinkenberg, Sylvia, Faber, Catharina G., Vles, Johan S.H., Hendriksen, Jos G.M. · 2019 · European Journal of Paediatric Neurology
Cited by 20

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejpn.2018.09.005

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 21

  1. Moat, 2013, Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK), Eur J Hum Genet, 21, 1049, 10.1038/ejhg.2012.301 · DOI · Paper page
  2. Yiu, 2015, Duchenne muscular dystrophy, J Paediatr Child Health, 51, 759, 10.1111/jpc.12868 · DOI · Paper page
  3. Hendriksen, 2008, Neuropsychiatric disorders in males with duchenne muscular dystrophy: frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive-compulsive disorder, J Child Neurol, 23, 477, 10.1177/0883073807309775 · DOI · Paper page
  4. Snow, 2013, Neuropsychological and neurobehavioral functioning in Duchenne muscular dystrophy: a review, Neurosci Biobehav Rev, 37, 743, 10.1016/j.neubiorev.2013.03.016 · DOI · Paper page
  5. Pane, 2012, Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation, J Pediatr, 161, 705, 10.1016/j.jpeds.2012.03.020 · DOI · Paper page
  6. Anderson, 2002, Brain function in Duchenne muscular dystrophy, Brain, 125, 4, 10.1093/brain/awf012 · DOI · Paper page
  7. Polanczyk, 2007, The worldwide prevalence of ADHD: a systematic review and metaregression analysis, Am J Psychiatr, 164, 942, 10.1176/ajp.2007.164.6.942 · DOI · Paper page
  8. Young, 2008, Cognitive and psychological profile of males with Becker muscular dystrophy, J Child Neurol, 23, 155, 10.1177/0883073807307975 · DOI
  9. Birnkrant, 2018, Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan, Lancet Neurol, 17, 445, 10.1016/S1474-4422(18)30026-7 · DOI · Paper page
  10. Greenhill, 2001, Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults, J Am Acad Child Adolesc Psychiatry, 40, 1352, 10.1097/00004583-200111000-00020 · DOI
  11. Hendriksen, 2018, Brain-related comorbidities in boys and men with Duchenne Muscular Dystrophy: a descriptive study, Eur J Paediatr Neurol, 22, 488, 10.1016/j.ejpn.2017.12.004 · DOI
  12. Hendriksen, 2015, Diagnostic overshadowing in a population of children with neurological disabilities: a cross sectional descriptive study on acquired ADHD, Eur J Paediatr Neurol, 19, 521, 10.1016/j.ejpn.2015.04.004 · DOI
  13. Birnkrant, 2018, Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management, Lancet Neurol, 17, 347, 10.1016/S1474-4422(18)30025-5 · DOI · Paper page
  14. Huss, 2017, Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity, Neuropsychiatr Dis Treat, 13, 1741, 10.2147/NDT.S130444 · DOI
  15. Konrad, 2004, Differential effects of methylphenidate on attentional functions in children with attention-deficit/hyperactivity disorder, J Am Acad Child Adolesc Psychiatry, 43, 191, 10.1097/00004583-200402000-00015 · DOI · Paper page
  16. Lidzba, 2014, Pharmacotherapy of attention deficit in neurofibromatosis type 1: effects on cognition, Neuropediatrics, 45, 240, 10.1055/s-0034-1368117 · doi:10.1055/s-0034-1368117
  17. Mautner, 2002, Treatment of ADHD in neurofibromatosis type 1, Dev Med Child Neurol, 44, 164, 10.1017/S0012162201001876 · DOI · Paper page
  18. Chang, 2016, Diagnostic accuracy of rating scales for attention-deficit/hyperactivity disorder: a meta-analysis, Pediatrics, 137, 10.1542/peds.2015-2749 · DOI · Paper page
  19. Volkow, 2003, Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma, Psychopharmacology (Berl), 166, 264, 10.1007/s00213-002-1340-7 · DOI
  20. Hennissen, 2017, Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine, CNS Drugs, 31, 199, 10.1007/s40263-017-0410-7 · DOI · Paper page
  21. Waschbusch, 2008, Parent and teacher ratings on the Iowa Conners rating scale, J Psychopathol Behav Assess, 30, 180, 10.1007/s10862-007-9064-y · DOI

Cited by

Metadata

Authors
Lionarons, J. M., Hellebrekers, D. M. J., Klinkenberg, S., Faber, C. G., Vles, J. S. H., & Hendriksen, J. G. M.
Venue
European Journal of Paediatric Neurology
Publisher
Elsevier BV
Published
2019-01
Volume
23
Issue
1
Pages
152-157
ISSN
1090-3798
Cited by
20
References
5
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • Spieren voor Spieren Foundation (SvS15-)
  • Duchenne Parent Project Netherlands (2016)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.